(Q35007865)

PubMed publication ID

12448863

5 August 2017

title

"Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

14 May 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

14 May 2020

author name string

Roy West

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

14 May 2020

E Keith Borden

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

14 May 2020

Jean-Paul Collet

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

14 May 2020

Robert S Tonks

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

14 May 2020

publication date

1 November 2002

1 reference

PubMed publication ID

12448863

Canadian Journal of Public Health

5 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

14 May 2020

volume

93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

14 May 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

14 May 2020

page(s)

421-425

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.

14 May 2020

cites work

1 reference

12 December 2020

Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.

1 reference

12 December 2020

Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

1 reference

12 December 2020

Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: a personal viewpoint.

1 reference

12 December 2020

Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States

1 reference

12 December 2020

Could conditional release of new drugs provide the information required to study drug effectiveness? - A discussion paper

1 reference

12 December 2020

"Effectiveness" in the evaluation of new drugs: a misunderstood concept?

1 reference

12 December 2020

A dog's breakfast: prescription drug coverage varies widely across Canada

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03405029

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6979820&resulttype=core&format=json

14 May 2020

PubMed publication ID

12448863

1 reference